Travade P, Chastang C, Dighiero G, Binet J L
Blood Cells. 1987;12(2):485-502.
We review here results obtained from the various treatment modalities that have been used in CLL patients: chemotherapy; radiotherapy; splenectomy; leukapheresis; monoclonal antibodies and other immunomodulating agents. We conclude that it is still unclear whether patients in stage A (good prognosis) should be treated; intermediate forms of the disease (stage B) should, in most cases, be treated, but a better treatment than chlorambucil has not emerged; results from the Cooperative Group on CLL of Société Française d'Hématologie indicate that significant progress in the therapy of the advanced stage (stage C) has been achieved with the introduction of the CHOP regimen, using low doses of adriamycin; radiotherapy, splenectomy and immunomodulators such as levamizol, interleukins or interferons, and possibly monoclonal antibodies, are now being actively tested; the results are not yet conclusive.
我们在此回顾了慢性淋巴细胞白血病（CLL）患者使用的各种治疗方式所取得的结果：化疗、放疗、脾切除术、白细胞去除术、单克隆抗体及其他免疫调节药物。我们得出结论，目前仍不清楚A期（预后良好）患者是否应接受治疗；大多数情况下，疾病的中间型（B期）应接受治疗，但尚未出现比苯丁酸氮芥更好的治疗方法；法国血液学会慢性淋巴细胞白血病协作组的结果表明，通过引入使用低剂量阿霉素的CHOP方案，晚期（C期）治疗已取得显著进展；放疗、脾切除术以及免疫调节剂如左旋咪唑、白细胞介素或干扰素，可能还有单克隆抗体，目前正在积极试验中；结果尚无定论。
